RESUMEN
Healthcare workers (HCWs) are at increased risk of both exposure and transmission of infectious disease. Two European Union (EU) directives state that health services are responsible for assessing their employees' potential exposure to infectious diseases and offering immunisation free of charge. We assessed current policy for immunisation of HCWs and the availability of vaccine coverage data in the Nordic countries by surveying national vaccination experts in Denmark, Finland, Iceland, Norway and Sweden, as well as Swedish county medical officers (CMOs). All national experts and 17 of 21 Swedish CMOs responded. All EU countries had transposed the European directives into national law, while Norway and Iceland had similar national legislation. Recommendations or guidelines were issued in Denmark, Finland, Iceland, Norway and 15 of 17 responding Swedish counties. The range of diseases covered differed by countries and Swedish counties. HCW vaccine coverage data were not systematically collected; incomplete estimates were only available for Finland and two Swedish counties. In conclusion, recommendations or guidelines exist in the Nordic countries, but their impact cannot be assessed, as vaccine uptake among HCWs is not currently measured. Systematic collection of data is a necessary step towards improving HCW immunisation policy and practice in the Nordic countries.
Asunto(s)
Personal de Salud , Vacunación , Finlandia , Humanos , Islandia/epidemiología , Noruega/epidemiología , Países Escandinavos y Nórdicos/epidemiología , Suecia/epidemiologíaRESUMEN
Immunity following natural infection or immunization may wane, increasing susceptibility to infection with time since infection or vaccination. Symptoms, and concomitantly infectiousness, depend on residual immunity. We quantify these phenomena in a model population composed of individuals whose susceptibility, infectiousness, and symptoms all vary with immune status. We also model age, which affects contact, vaccination and possibly waning rates. The resurgences of pertussis that have been observed wherever effective vaccination programs have reduced typical disease among young children follow from these processes. As one example, we compare simulations with the experience of Sweden following resumption of pertussis vaccination after the hiatus from 1979 to 1996, reproducing the observations leading health authorities to introduce booster doses among school-aged children and adolescents in 2007 and 2014, respectively. Because pertussis comprises a spectrum of symptoms, only the most severe of which are medically attended, accurate models are needed to design optimal vaccination programs where surveillance is less effective.
Asunto(s)
Tos Ferina , Adolescente , Niño , Preescolar , Humanos , Inmunización , Programas de Inmunización , Inmunización Secundaria , Vacunación , Tos Ferina/epidemiología , Tos Ferina/prevención & controlRESUMEN
We investigated and compared current national vaccination policies for health-care personnel (HCP) in Europe with results from our previous survey. Data from 36 European countries were collected using the same methodology as in 2011. National policies for HCP immunization were in place in all countries. There were significant differences in terms of number of vaccinations, target HCP and healthcare settings, and implementation regulations (recommended or mandatory vaccinations). Vaccination policies against hepatitis B and seasonal influenza were present in 35 countries each. Policies for vaccination of HCP against measles, mumps, rubella and varicella existed in 28, 24, 25 and 19 countries, respectively; and against tetanus, diphtheria, pertussis and poliomyelitis in 21, 20, 19, and 18 countries, respectively. Recommendations for hepatitis A immunization existed in 17 countries, and against meningococcus B, meningococcus C, meningococcus A, C, W, Y, and tuberculosis in 10, 8, 17, and 7 countries, respectively. Mandatory vaccination policies were found in 13 countries and were a pre-requisite for employment in ten. Comparing the vaccination programs of the 30 European countries that participated in the 2011 survey, we found that more countries had national vaccination policies against measles, mumps, rubella, hepatitis A, diphtheria, tetanus, poliomyelitis, pertussis, meningococcus C and/or meningococcus A, C, W, Y; and more of these implemented mandatory vaccination policies for HCP. In conclusion, European countries now have more comprehensive national vaccination programs for HCP, however there are still gaps. Given the recent large outbreaks of vaccine-preventable diseases in Europe and the occupational risk for HCP, vaccination policies need to be expanded and strengthened in several European countries. Overall, vaccination policies for HCP in Europe should be periodically re-evaluated in order to provide optimal protection against vaccine-preventable diseases and infection control within healthcare facilities for HCP and patients.
Asunto(s)
Personal de Salud , Política de Salud , Programas de Inmunización/legislación & jurisprudencia , Vacunación/legislación & jurisprudencia , Europa (Continente) , Humanos , Programas Obligatorios/legislación & jurisprudencia , Salud LaboralRESUMEN
Serological surveys provide reliable information from which to calculate forces (instantaneous rates) of infection, but waning immunity and clinical consequences that depend on residual immunity complicate interpretation of results. We devised a means of calculating these rates that accounts for passively acquired maternal antibodies that decay or active immunity that wanes, permitting re-infection. We applied our method to pertussis (whooping cough) in Sweden, where vaccination was discontinued from 1979 to 1995. A national cross-sectional serosurvey of antibodies to pertussis toxin, which peak soon after infection and then decay, was conducted shortly after vaccination resumed. Together with age-specific contact rates in Finland, contemporary forces of infection enable us to evaluate the recent assertion that the probability of infection upon contact is age-independent. We find elevated probabilities among children, adolescents and young adults, whose contacts may be more intimate than others. Products of contact rates and probabilities of infection permit transmission modeling and estimation of the intrinsic reproduction number. In contrast to another recent estimate, ours approximates the ratio of life expectancy and age at first infection. Our framework is sufficiently general to accommodate more realistic sojourn distributions and additional lifetime infections.
Asunto(s)
Anticuerpos Antibacterianos/inmunología , Bordetella pertussis/inmunología , Intercambio Materno-Fetal/inmunología , Modelos Biológicos , Tos Ferina/inmunología , Tos Ferina/transmisión , Adolescente , Edad de Inicio , Niño , Preescolar , Estudios Transversales , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Embarazo , Suecia/epidemiología , Vacunación , Tos Ferina/epidemiología , Tos Ferina/prevención & controlAsunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/administración & dosificación , Vacunación Masiva , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/biosíntesis , Niño , Vacuna contra Difteria, Tétanos y Tos Ferina/efectos adversos , Femenino , Humanos , Inmunización Secundaria , Masculino , Estudios Prospectivos , SueciaRESUMEN
Sweden was the only country in the world without any general pertussis vaccination when acellular pertussis (aP) vaccines were introduced. Since 1996 aP vaccines are given at the ages of 3, 5 and 12 months, with a 99% coverage, and until 2007 without a later booster. The long-term effects of aP vaccines, monitored within an enhanced surveillance project, were discussed at an international workshop in Stockholm in November 2008. The unique Swedish experience demonstrates that aP vaccines are capable of achieving the primary goal of a national vaccination programme, i.e., to significantly reduce the burden of pertussis in pre-school children. Throughout the 10-year surveillance period the highest age-specific incidence was reported in unvaccinated infants or those who had received only one dose, with most hospitalisations in this age group and eight deaths among unvaccinated infants. Complementary strategies are needed to achieve further reduction in morbidity from circulation of Bordetella pertussis.
Asunto(s)
Programas de Inmunización , Vacuna contra la Tos Ferina/administración & dosificación , Vigilancia de la Población , Tos Ferina/prevención & control , Niño , Notificación de Enfermedades , Estudios de Seguimiento , Humanos , Suecia/epidemiología , Tos Ferina/epidemiologíaAsunto(s)
Programas de Inmunización , Esquemas de Inmunización , Adolescente , Niño , Preescolar , Unión Europea , Humanos , Inmunización Secundaria , LactanteRESUMEN
BACKGROUND: Herpes simplex virus type 1 (HSV-1) infections are commonly acquired in childhood, asymptomatically or as a symptomatic infection. However, little is known about the time of HSV seroconversion during infancy and early childhood. OBJECTIVE: To investigate the acquisition of IgG-antibodies to HSV in infants and children. STUDY DESIGN: A longitudinal study, using type-specific HSV-1 and herpes simplex virus type 2 (HSV-2) enzyme-linked immunosorbent assays on sera collected from the mother and from their child at the age of 3, 5, 6, 12, 13 and 30 months. RESULTS: The maternal seroprevalences for HSV-1 was 65% and for HSV-2 19%. A gradual loss of maternal antibodies was seen, with few infants having detectable HSV-1 antibodies at the age of 1 year. A more rapid decline was registered for HSV-2 antibodies. A small number of new HSV-1 infections occurred in 3-5-month olds and more than half of the new infections were detected before the age of 13 months. At the age of 30 months, 30% of the children were HSV-1 antibody positive. CONCLUSION: Seroconversion to HSV-1 commonly occurs already during infancy, suggesting that HSV-1 is transmitted primarily from parent to child.
Asunto(s)
Anticuerpos Antivirales/sangre , Herpes Simple/epidemiología , Herpesvirus Humano 1/inmunología , Herpesvirus Humano 2/inmunología , Preescolar , Femenino , Herpes Simple/transmisión , Humanos , Lactante , Transmisión Vertical de Enfermedad Infecciosa , Estudios Longitudinales , Masculino , Embarazo , Complicaciones Infecciosas del Embarazo , Estudios SeroepidemiológicosRESUMEN
In Sweden, acellular pertussis vaccines were introduced at 3, 5 and 12 months of age in 1996, after a 17-year hiatus without pertussis vaccination. An intensified surveillance of pertussis was initiated in October 1997, including collection of clinical data as well as Bordetella pertussis isolates in culture or PCR-confirmed cases of pertussis among children born from January 1996 to September 2004. We analysed the association of pulsed-field gel electrophoresis (PFGE) profile and serotype with severity of disease for all children followed during the first 7 years of the project. There were in all 927 children for whom both clinical information and strain characterisation data were available. 260 of these children were hospitalised during the pertussis episode. When duration of hospital stay was compared between children with different groups of strains, characterised by PFGE profile or serotype, there was a significantly higher proportion of children with long duration of hospital stay in the most frequent PFGE profile group (BpSR11) compared to the PFGE group of all other profiles (p=0.041). There was no statistically significant association between serotype and hospitalisation rate or duration of hospital stay, neither was there any statistically significant association between serotype or PFGE profile and duration of spasmodic cough or presence of complications.
Asunto(s)
Bordetella pertussis/química , Vacuna contra Difteria, Tétanos y Tos Ferina/administración & dosificación , Tos Ferina/inmunología , Niño , Vacuna contra Difteria, Tétanos y Tos Ferina/inmunología , Electroforesis en Gel de Campo Pulsado , Humanos , Vigilancia de la Población , Serotipificación , Suecia/epidemiología , Vacunación , Tos Ferina/clasificación , Tos Ferina/epidemiología , Tos Ferina/prevención & controlRESUMEN
The article presents clinical features of pertussis in older children and adults as well as in unvaccinated infants, with the aim to increase the awareness of the disease and to promote implementation of chemoprophylaxis in households with infants. The national routines for reporting according to the Communicable Diseases Act are outlined, contact-tracing around cases of pertussis being mandatory since July 2004.
Asunto(s)
Control de Enfermedades Transmisibles , Trazado de Contacto , Tos Ferina/prevención & control , Adulto , Antibacterianos/administración & dosificación , Niño , Notificación de Enfermedades , Humanos , Lactante , Vacuna contra la Tos Ferina/administración & dosificación , Factores de Riesgo , Tos Ferina/diagnóstico , Tos Ferina/tratamiento farmacológico , Tos Ferina/mortalidadRESUMEN
Acellular pertussis vaccine was introduced in Sweden in 1996 at the age of 3, 5 and 12 months, after a 17 year period without general vaccination against pertussis. At present, the incidence of notified pertussis has decreased to 1/10 of what was seen 10 years ago. In spite of the dramatic decrease, the disease is not eliminated. In accordance with the experience of other countries, most cases in Sweden are reported among older children and adults, while the highest risk of severe disease is still seen in infants. Many industrialized countries have introduced booster dose(s) in order to control the spread of pertussis. The Swedish National Board of Health and Welfare has recently initiated a major revision of the vaccines used and the schedule of the national vaccination program. Until the final proposal and in order not to miss the opportunity to boost pertussis immunity in children who were vaccinated as infants at the reintroduction of pertussis vaccination, the Board now recommends the Swedish municipalities as an interim measure to include pertussis in the current school booster against diphtheria and tetanus at 10 years of age with a full dose vaccine.
Asunto(s)
Vacuna contra Difteria, Tétanos y Tos Ferina/administración & dosificación , Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/administración & dosificación , Inmunización Secundaria , Vacuna contra la Tos Ferina/administración & dosificación , Tos Ferina/prevención & control , Adulto , Niño , Humanos , Inmunización Secundaria/economía , Incidencia , Lactante , Vacunación Masiva/organización & administración , Suecia/epidemiología , Tos Ferina/epidemiologíaRESUMEN
The Swedish population of Bordetella pertussis strains was characterized from 1,247 isolates covering a whole-cell vaccine program up to 1979, a 17-year period without vaccination (1979 to 1996), and a period after the introduction of general vaccination among newborns with acellular pertussis vaccines (1997 to 2003). Strains were characterized by serotyping and genotyping of pertactin and ptxA and by means of pulsed-field gel electrophoresis (PFGE). With emphasis on vaccine-related markers, the vast majority of circulating strains were of nonvaccine type. There were shifts of serotype connected with shifts of vaccination program. Serotype Fim3 was most frequent during the periods with general vaccination schedules, whereas serotype Fim2 was predominant during the 17-year vaccine-free period. Pertactin 1 was predominant during the pertussis whole-cell (Pw) vaccine period but was thereafter replaced by prn2 and has not reappeared after the introduction of acellular pertussis (Pa) vaccines. ptxA (1) was predominant over all three decades. There was a significant difference in the distribution of serotypes between vaccinated and unvaccinated individuals, but not for pertactin. A few PFGE profiles were predominant over the years: BpSR25 (serotype Fim3 prn1/7) and BpSR18 (serotype Fim3 prn2) during the Pw period, BpSR1 (serotype Fim2 prn2) during the 17 years without general vaccination, and BpSR11 (serotype Fim3 prn2) after the reintroduction of general vaccination in 1996. Despite differences between the pertactin and toxin types of Pa vaccines and circulating strains, there is no evidence that there is a threat, i.e., the vaccination program so far has been effective against whooping cough, and there seems to be no impact on the effectiveness of the vaccination program from the bacterial polymorphism.
Asunto(s)
Bordetella pertussis/clasificación , Bordetella pertussis/genética , Variación Genética , Programas de Inmunización/métodos , Vacuna contra la Tos Ferina/administración & dosificación , Vacunas Acelulares/administración & dosificación , Tos Ferina/epidemiología , Proteínas de la Membrana Bacteriana Externa/genética , Bordetella pertussis/aislamiento & purificación , Niño , Preescolar , Electroforesis en Gel de Campo Pulsado , Genotipo , Humanos , Recién Nacido , Toxina del Pertussis/genética , Serotipificación , Suecia/epidemiología , Vacunación , Factores de Virulencia de Bordetella/genética , Tos Ferina/microbiologíaRESUMEN
BACKGROUND: Antibody persistence was studied in 5.5-year-old Swedish children who in infancy completed a vaccine trial of a combined diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated polio and Haemophilus influenzae type b conjugate vaccine. Three priming doses at ages 2-4-6 months induced higher geometric mean concentrations of antibodies for all antigens than did two doses at 3-5 months, but there were no differences in proportions with protective antibody concentrations. After the booster dose administered at 13 or 12 months of age, respectively, there were no differences in concentrations or proportions between the groups. METHODS: In the present follow-up serum samples from 180 of the 228 vaccinees, 88 from the 4-dose and 92 from the 3-dose group, were 4.5 years later again tested for antibodies. RESULTS: The two groups did not differ significantly in antibody concentrations or proportions with antibodies above protective or other defined levels, with the exception of poliovirus type 3 (P < or = 0.01). In all 89% had > or = 0.01 IU/ml antibodies against diphtheria by enzyme-linked immunosorbent assay and 76% by the Vero cell neutralization test, 93% had > or = 0.01 IU/ml antibodies against tetanus, 96 to 99% had detectable antibodies against the polioviruses and 97% had > or = 0.15 microg/ml H. influenzae type b antibodies. As for pertussis only 44% had detectable antibodies against pertussis toxoid by enzyme-linked immunosorbent assay but 99% by Chinese hamster ovary cell neutralization test, and 94% had detectable antibodies against filamentous hemagglutinin. CONCLUSION: We found the persistence of antibodies satisfactory, with no clinically relevant differences in antibody concentrations demonstrated between children vaccinated according to a three dose or a four dose schedule in infancy.